Precision Medicine

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

With major investor conferences ahead, Ceribell showcases impressive revenue growth fueled by its AI-driven EEG system and a string of new FDA clearances.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

A landmark study finds nearly half of Americans use OTC drugs weekly, revealing a quiet revolution in self-care that challenges current healthcare policy.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

After two decades of global use, Fziomed's anti-adhesion gel has treated one million patients, signaling a major shift in post-surgical recovery.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

The luxury gym now accepts pre-tax health funds for memberships, signaling a major shift where high-end fitness is becoming a form of prescribed medicine.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

A new tool, SpecKit, built on Form.io's platform, aims to solve a critical bottleneck in healthcare by simplifying the creation of FHIR test data.

Annexon Biosciences spotlights its novel C1q inhibitor, Vonaprument, aiming to be the first therapy to preserve vision in geographic atrophy patients.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.